InvestorsHub Logo
Followers 253
Posts 17893
Boards Moderated 0
Alias Born 01/19/2006

Re: DewDiligence post# 343

Monday, 09/26/2016 1:43:56 PM

Monday, September 26, 2016 1:43:56 PM

Post# of 1162
You are correct there too....MRK, AZN and Roche will prove to be worthy competitors in immuno-oncology after BMY's fast start. Do you agree with many oncologists that BMY needs to find some co-therapy that will increase RRRs of both Opdivo and Yervoy, without subsequent tumor cell mutations mitigating PFS or OS?

I will be interested to see what may emanate from ESMO in early October as well as MSK and NCCN clinical trials.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News